Drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route, writes Katrine Bosley, former CEO of Avila Therapeutics. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Two-way, iterative partnerships bring together big drugmakers' experience with small biotechs' innovation, Bosley writes.
Innovation supply chain model risks "teaching to the test"
SmartBrief Job Listings for Health Care
|MGR POST MARKET STUDIES - 14000001LK||
|Santa Ana, CA|
|Program Coordinator/Lecturer for the Regulatory Science program||
Johns Hopkins University
|Eastern Zone Sales Director||
|Multiple Locations, SL_Multiple Locations|
|Senior Financial Analyst - Growing Manager Care Health Org||
Fallon Community Health Plan